Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Stacey J Adam"'
Autor:
Phuoc T Tran, Emelyn H Shroff, Timothy F Burns, Saravanan Thiyagarajan, Sandhya T Das, Tahera Zabuawala, Joy Chen, Yoon-Jae Cho, Richard Luong, Pablo Tamayo, Tarek Salih, Khaled Aziz, Stacey J Adam, Silvestre Vicent, Carsten H Nielsen, Nadia Withofs, Alejandro Sweet-Cordero, Sanjiv S Gambhir, Charles M Rudin, Dean W Felsher
Publikováno v:
PLoS Genetics, Vol 8, Iss 5, p e1002650 (2012)
KRAS mutant lung cancers are generally refractory to chemotherapy as well targeted agents. To date, the identification of drugs to therapeutically inhibit K-RAS have been unsuccessful, suggesting that other approaches are required. We demonstrate in
Externí odkaz:
https://doaj.org/article/888bf29c10e84b71a81ce396c6901816
Autor:
Stacey J. Adam, Timothy G. Buchman, Judith S. Currier, Ruxandra Draghia-Akli, Josh P. Fessel, Elizabeth S. Higgs, Eric A. Hughes, Lisa LaVange, Joseph P. Menetski, Sarah W. Read, Yves Rosenberg, Randall Tressler, ACTIV Therapeutics-Clinical Working Group
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
The Accelerating COVID-19 Therapeutic Interventions and Vaccines Therapeutic-Clinical Working Group members gathered critical recommendations in follow-up to lessons learned manuscripts released earlier in the COVID-19 pandemic. Lessons around agent
Externí odkaz:
https://doaj.org/article/a7c8b5fb4a0045bfa8f5cc35ccb6d74c
Autor:
David A. Wohl, Stacey J. Adam, Kevin W. Gibbs, Ari L. Moskowitz, Thomas L. Ortel, Upinder Singh, Nikolaus Jilg, Teresa H. Evering, William A. Fischer, Babafemi O. Taiwo, Eric S. Daar, Christopher J. Lindsell, Susanna Naggie, Russell L. Rothman, Sarah E. Dunsmore, M. Patricia McAdams, Julia Vail, Dushyantha Jayaweera
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
This manuscript addresses a critical topic: navigating complexities of conducting clinical trials during a pandemic. Central to this discussion is engaging communities to ensure diverse participation. The manuscript elucidates deliberate strategies e
Externí odkaz:
https://doaj.org/article/910db551481c4638b1522107df421ace
Autor:
Maryam Keshtkar-Jahromi, Kevin J. Anstrom, Christina Barkauskas, Samuel M. Brown, Eric S. Daar, William Fischer, Kevin W. Gibbs, Elizabeth S. Higgs, Michael D. Hughes, Prasanna Jagannathan, Lisa LaVange, Christopher J. Lindsell, Seema U. Nayak, Roger Paredes, Mahesh Parmar, Ithan D. Peltan, Michael Proschan, Matthew S. Shotwell, David M. Vock, Tammy Yokum, Stacey J. Adam
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group selected ACTIV trial t
Externí odkaz:
https://doaj.org/article/7e2590f8d0ee49e1b99ef50a2cfc40d2
Autor:
Maryam Keshtkar-Jahromi, Stacey J. Adam, Indira Brar, Lucy K. Chung, Judith S. Currier, Eric S. Daar, Victoria J. Davey, Eileen T. Denning, Annetine C. Gelijns, Elizabeth S. Higgs, Prasanna Jagannathan, Arzhang Cyrus Javan, Tomas O. Jensen, Nikolaus Jilg, Ioannis Kalomenidis, Peter Kim, Seema U. Nayak, Matthew Newell, Babafemi O. Taiwo, Tammy Yokum, Yvette Delph
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
The United States Government (USG) public-private partnership “Accelerating COVID-19 Treatment Interventions and Vaccines” (ACTIV) was launched to identify safe, effective therapeutics to treat patients with Coronavirus Disease 2019 (COVID-19) an
Externí odkaz:
https://doaj.org/article/b429d74352644bba8ed889493a0a3109
Publikováno v:
Journal of Clinical and Translational Science, Vol 8 (2024)
Externí odkaz:
https://doaj.org/article/a6da7cf79feb4a68b3b766a044045b2a
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1175-1182
Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic health records, medical imaging, genomic sequencing, payor records, and data from pharmaceutica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71f4d3e129a9c64d20c7837ca7bd3bb5
https://doi.org/10.1158/0008-5472.can-22-1274
https://doi.org/10.1158/0008-5472.can-22-1274
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis D. Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo H. Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1183-1190
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9042c740550e4c3e4949faea3069c247
https://doi.org/10.1158/0008-5472.can-22-1277
https://doi.org/10.1158/0008-5472.can-22-1277
Autor:
Delaney K. Sullivan, Anja Deutzmann, Josiah Yarbrough, Maya S. Krishnan, Arvin M. Gouw, David I. Bellovin, Stacey J. Adam, Daniel F. Liefwalker, Renumathy Dhanasekaran, Dean W. Felsher
Publikováno v:
Oncogene. 41:4960-4970
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3eb64b45b6309a74b1576bf01221b33
https://doi.org/10.1038/s41388-022-02458-9
https://doi.org/10.1038/s41388-022-02458-9
Autor:
Susanna, Naggie, David R, Boulware, Christopher J, Lindsell, Thomas G, Stewart, Nina, Gentile, Sean, Collins, Matthew William, McCarthy, Dushyantha, Jayaweera, Mario, Castro, Mark, Sulkowski, Kathleen, McTigue, Florence, Thicklin, G Michael, Felker, Adit A, Ginde, Carolyn T, Bramante, Alex J, Slandzicki, Ahab, Gabriel, Nirav S, Shah, Leslie A, Lenert, Sarah E, Dunsmore, Stacey J, Adam, Allison, DeLong, George, Hanna, April, Remaly, Rhonda, Wilder, Sybil, Wilson, Elizabeth, Shenkman, Adrian F, Hernandez, Nicole, Zaleski
Publikováno v:
medRxiv
JAMA
JAMA
ImportanceThe effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown.ObjectiveTo evaluate the efficacy of ivermectin, 400 μg/kg, daily for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3731a8e449b37d0ea83be17c95083061
https://pubmed.ncbi.nlm.nih.gov/36561174
https://pubmed.ncbi.nlm.nih.gov/36561174